Compared side by side
IGF-1 LR3 vs PEG-MGF: how they differ
The short answer
Both are built from IGF-1: IGF-1 LR3 is a lab-modified IGF-1 that escapes its binding proteins and reaches the IGF-1 receptor, and PEG-MGF is the 24-amino-acid tail of a muscle variant of IGF-1 (mechano growth factor) with polyethylene glycol attached to make it last longer. In cell studies mechano growth factor pushed muscle precursor cells to multiply, but two drug companies failed to reproduce those effects. Neither has published human studies, and no study of the PEGylated form has been published at all.
Side by side
| Compared | IGF-1 LR3 | PEG-MGF |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | Long R3 IGF-1, LR3 IGF-1, LongR3-IGF-I, Long [Arg3] IGF-I, IGF1 LR3, IGF-1 Long R3 | Mechano Growth Factor, MGF, PEGylated MGF, IGF-1Ec, IGF-1 Ec peptide, MGF E-peptide |
| What it is | IGF-1 is the growth factor your liver and muscles make when growth hormone arrives — the messenger that does much of GH's building work. | When muscle is loaded or damaged, the IGF-1 gene can be read a different way, producing a variant with an extra tail. |
| How it works | A laboratory-built version of IGF-1: human IGF-1 with glutamate at position 3 swapped for arginine and an 11-amino-acid tail from pig growth hormone added to the front. Both changes do one thing — they make it bind the IGF-binding proteins about a thousand times more weakly, so it circulates free and reaches the IGF-1 receptor instead of being held in reserve. That is where its extra potency comes from, not from a stronger signal: in cells that make no binding proteins it is weaker than IGF-1. In rats it grew body weight, gut and organs; in pigs the same infusion did the opposite and suppressed their own GH, insulin and IGF-1. No human study of it has been published. | The 24-amino-acid tail of IGF-1Ec, a splice variant of the IGF-1 gene that muscle turns up after loading or injury; the tail is cut off when the gene product is processed, and that fragment is what is sold as mechano growth factor. In cell studies it pushed muscle precursor cells to multiply and held back their fusion into fibers — the opposite half of what mature IGF-1 does — and blocking the IGF-1 receptor did not stop it, which is read as a separate receptor nobody has identified. Two pharmaceutical companies then failed to reproduce any of those cell effects. The PEG version attaches polyethylene glycol to slow the peptide's breakdown; no study of the PEGylated form has been published at all. |
| Commonly reported | Fuller muscles and quicker recovery, hunger, and the shaky, sweaty, light-headed feeling of a blood-sugar dip within an hour or two of a dose. There are no human studies of it, and low blood sugar is the one documented risk of the class. | Very little you can feel, sometimes local soreness or fullness, which fits a peptide with no systemic signal to give. Its cell evidence is genuinely disputed: the group that discovered the effect and two drug companies that tried to repeat it reached opposite results. |
| Studied range | Research range: 20–50 mcg, starting dose 20 mcg. Studied in research — not a recommendation. | Research range: 200–400 mcg, starting dose 200 mcg. Studied in research — not a recommendation. |
| How often | Daily (community protocols: training days) | 2–3x weekly, post-workout |
| Half-life | Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured. | Not measured: no pharmacokinetic study of PEG-MGF has been published, in people or in animals. The unmodified peptide is broken down quickly, and for a mouse heart study researchers stabilized it chemically — amidating one end and swapping two arginines for their mirror-image form (Mavrommatis 2013); attaching PEG is a standard way to slow that clearance. The 48-to-72-hour figure community guides quote has never been measured. |
| Route | SubQ injection | SubQ injection, IM injection |
| Typical run | Community cycles commonly run 3 to 6 weeks with an equal or longer break, on the belief that the IGF-1 receptor downregulates; no study has tested that in people. The animal work that found it anabolic used continuous infusion from an implanted pump over 7 to 14 days; given as daily injections it worked much less well than by infusion, though it still beat plain IGF-1 on several measures (not on muscle loss in catabolic rats). | Community cycles commonly run 8 to 16 weeks with about a 4-week break, often with a stepped-up loading phase at the start; none of that comes from a study. The animal experiments were single or short courses of locally delivered peptide, mostly within days of an injury. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache | Injection site reaction, local soreness, generally little felt |
- Category
- IGF-1 LR3Growth hormone
- PEG-MGFGrowth hormone
- Also known as
- IGF-1 LR3Long R3 IGF-1, LR3 IGF-1, LongR3-IGF-I, Long [Arg3] IGF-I, IGF1 LR3, IGF-1 Long R3
- PEG-MGFMechano Growth Factor, MGF, PEGylated MGF, IGF-1Ec, IGF-1 Ec peptide, MGF E-peptide
- What it is
- IGF-1 LR3IGF-1 is the growth factor your liver and muscles make when growth hormone arrives — the messenger that does much of GH's building work.
- PEG-MGFWhen muscle is loaded or damaged, the IGF-1 gene can be read a different way, producing a variant with an extra tail.
- How it works
- IGF-1 LR3A laboratory-built version of IGF-1: human IGF-1 with glutamate at position 3 swapped for arginine and an 11-amino-acid tail from pig growth hormone added to the front. Both changes do one thing — they make it bind the IGF-binding proteins about a thousand times more weakly, so it circulates free and reaches the IGF-1 receptor instead of being held in reserve. That is where its extra potency comes from, not from a stronger signal: in cells that make no binding proteins it is weaker than IGF-1. In rats it grew body weight, gut and organs; in pigs the same infusion did the opposite and suppressed their own GH, insulin and IGF-1. No human study of it has been published.
- PEG-MGFThe 24-amino-acid tail of IGF-1Ec, a splice variant of the IGF-1 gene that muscle turns up after loading or injury; the tail is cut off when the gene product is processed, and that fragment is what is sold as mechano growth factor. In cell studies it pushed muscle precursor cells to multiply and held back their fusion into fibers — the opposite half of what mature IGF-1 does — and blocking the IGF-1 receptor did not stop it, which is read as a separate receptor nobody has identified. Two pharmaceutical companies then failed to reproduce any of those cell effects. The PEG version attaches polyethylene glycol to slow the peptide's breakdown; no study of the PEGylated form has been published at all.
- Commonly reported
- IGF-1 LR3Fuller muscles and quicker recovery, hunger, and the shaky, sweaty, light-headed feeling of a blood-sugar dip within an hour or two of a dose. There are no human studies of it, and low blood sugar is the one documented risk of the class.
- PEG-MGFVery little you can feel, sometimes local soreness or fullness, which fits a peptide with no systemic signal to give. Its cell evidence is genuinely disputed: the group that discovered the effect and two drug companies that tried to repeat it reached opposite results.
- Studied range
- IGF-1 LR3Research range: 20–50 mcg, starting dose 20 mcg. Studied in research — not a recommendation.
- PEG-MGFResearch range: 200–400 mcg, starting dose 200 mcg. Studied in research — not a recommendation.
- How often
- IGF-1 LR3Daily (community protocols: training days)
- PEG-MGF2–3x weekly, post-workout
- Half-life
- IGF-1 LR3Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured.
- PEG-MGFNot measured: no pharmacokinetic study of PEG-MGF has been published, in people or in animals. The unmodified peptide is broken down quickly, and for a mouse heart study researchers stabilized it chemically — amidating one end and swapping two arginines for their mirror-image form (Mavrommatis 2013); attaching PEG is a standard way to slow that clearance. The 48-to-72-hour figure community guides quote has never been measured.
- Route
- IGF-1 LR3SubQ injection
- PEG-MGFSubQ injection, IM injection
- Typical run
- IGF-1 LR3Community cycles commonly run 3 to 6 weeks with an equal or longer break, on the belief that the IGF-1 receptor downregulates; no study has tested that in people. The animal work that found it anabolic used continuous infusion from an implanted pump over 7 to 14 days; given as daily injections it worked much less well than by infusion, though it still beat plain IGF-1 on several measures (not on muscle loss in catabolic rats).
- PEG-MGFCommunity cycles commonly run 8 to 16 weeks with about a 4-week break, often with a stepped-up loading phase at the start; none of that comes from a study. The animal experiments were single or short courses of locally delivered peptide, mostly within days of an injury.
- Evidence
- IGF-1 LR3Emerging: primarily preclinical / limited human data
- PEG-MGFEmerging: primarily preclinical / limited human data
- Common side effects
- IGF-1 LR3Low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache
- PEG-MGFInjection site reaction, local soreness, generally little felt
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
IGF-1 LR3
- Day 1–14 Low blood sugar is the thing to know first
- Day 1–21 What people notice in the first weeks
- Day 14–42 What the animal studies actually showed
- Day 21–56 The 20–30 hour half-life is not a measurement
- Day 42+ Past six weeks: nothing is mapped
PEG-MGF
- Day 1–14 Expect nothing systemic to feel
- Day 14–42 Multiply first, repair after
- Day 28–84 Where the animal evidence is actually strongest
- Day 84+ Past twelve weeks, nothing has been studied anywhere
Together or one or the other
IGF-1 LR3 and PEG-MGF are a common stack: PEG-MGF lists IGF-1 LR3 among its common stacks.
Community · PEG-MGF
Two halves of the same gene
The pairing people reach for is exactly the biology: IGF-1 LR3 is the mature half of the molecule, PEG-MGF the tail the body cuts off it. As MGF's discoverers describe it, the tail recruits muscle stem cells and the mature peptide tells them to build. Both are research-only, and the glucose risk in the pair comes from the IGF-1 side alone.
Questions people ask
How long do IGF-1 LR3 and PEG-MGF last?
The half-life of IGF-1 LR3 is not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured. The half-life of PEG-MGF is not measured: no pharmacokinetic study of PEG-MGF has been published, in people or in animals. The unmodified peptide is broken down quickly, and for a mouse heart study researchers stabilized it chemically — amidating one end and swapping two arginines for their mirror-image form (Mavrommatis 2013); attaching PEG is a standard way to slow that clearance. The 48-to-72-hour figure community guides quote has never been measured.
How often are IGF-1 LR3 and PEG-MGF taken?
IGF-1 LR3: daily (community protocols: training days). Route: SubQ injection. PEG-MGF: 2–3x weekly, post-workout. Routes: SubQ injection, IM injection.
How are IGF-1 LR3 and PEG-MGF dosed in research?
The research range for IGF-1 LR3 is 20–50 mcg, with a 20 mcg starting dose. The research range for PEG-MGF is 200–400 mcg, with a 200 mcg starting dose. Studied in research — not a recommendation.
What are the common side effects of IGF-1 LR3 and PEG-MGF?
For IGF-1 LR3, the library lists: low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache. For PEG-MGF: injection site reaction, local soreness, generally little felt.
Are IGF-1 LR3 and PEG-MGF taken together?
IGF-1 LR3 and PEG-MGF are a common stack: PEG-MGF lists IGF-1 LR3 among its common stacks. The pairing people reach for is exactly the biology: IGF-1 LR3 is the mature half of the molecule, PEG-MGF the tail the body cuts off it. As MGF's discoverers describe it, the tail recruits muscle stem cells and the mature peptide tells them to build. Both are research-only, and the glucose risk in the pair comes from the IGF-1 side alone.